Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 33
- Registration Number
- NCT01877005
- Locations
- 🇫🇷
Chu Cote de Nacre, Caen, France
🇫🇷Hopital Henri Mondor, Creteil, France
🇧🇪UCL Louvain St Luc, Brussels, Belgium
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT01822756
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2022-09-22
- Target Recruit Count
- 50
- Registration Number
- NCT01776723
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01751425
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib for Chuvash Polycythemia
- Conditions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01730755
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Ruxolitinib for Adult T-Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT01712659
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT01712308
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2021-01-05
- Target Recruit Count
- 11
- Registration Number
- NCT01702064
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 15
- Registration Number
- NCT01693601
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
- Conditions
- Interventions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01632904
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.